A systematic review on the effect of HIV infection on the pharmacokinetics of first-line tuberculosis drugs
A Daskapan, LR Idrus, MJ Postma, B Wilffert… - Clinical …, 2019 - Springer
Introduction Contrasting findings have been published regarding the effect of human
immunodeficiency virus (HIV) on tuberculosis (TB) drug pharmacokinetics (PK). Objectives …
immunodeficiency virus (HIV) on tuberculosis (TB) drug pharmacokinetics (PK). Objectives …
Drug concentration thresholds predictive of therapy failure and death in children with tuberculosis: bread crumb trails in random forests
S Swaminathan, JG Pasipanodya… - Clinical Infectious …, 2016 - academic.oup.com
Background. The role of drug concentrations in clinical outcomes in children with
tuberculosis is unclear. Target concentrations for dose optimization are unknown. Methods …
tuberculosis is unclear. Target concentrations for dose optimization are unknown. Methods …
Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines
There are limited pharmacokinetic data for use of the first-line antituberculosis drugs during
infancy (< 12 months of age), when drug disposition may differ. Intensive pharmacokinetic …
infancy (< 12 months of age), when drug disposition may differ. Intensive pharmacokinetic …
Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection
Background Pharmacokinetic data on the first-line antituberculosis drugs using the World
Health Organization (WHO) revised dosages for children are limited. We investigated the …
Health Organization (WHO) revised dosages for children are limited. We investigated the …
Pharmacokinetics of the first-line antituberculosis drugs in Ghanaian children with tuberculosis with or without HIV coinfection
S Antwi, H Yang, A Enimil, AM Sarfo… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Although human immunodeficiency virus (HIV) coinfection is the most important risk factor
for a poor antituberculosis (anti-TB) treatment response, its effect on the pharmacokinetics of …
for a poor antituberculosis (anti-TB) treatment response, its effect on the pharmacokinetics of …
Suboptimal Antituberculosis drug concentrations and outcomes in small and HIV‐Coinfected children in India: recommendations for dose modifications
B Guiastrennec, G Ramachandran… - Clinical …, 2018 - Wiley Online Library
This work aimed to evaluate the once‐daily antituberculosis treatment as recommended by
the new Indian pediatric guidelines. Isoniazid, rifampin, and pyrazinamide concentration …
the new Indian pediatric guidelines. Isoniazid, rifampin, and pyrazinamide concentration …
A long-term co-perfused disseminated tuberculosis-3D liver hollow fiber model for both drug efficacy and hepatotoxicity in babies
S Srivastava, JG Pasipanodya, G Ramachandran… - …, 2016 - thelancet.com
Abstract Treatment of disseminated tuberculosis in children≤ 6years has not been
optimized. The pyrazinamide-containing combination regimen used to treat disseminated …
optimized. The pyrazinamide-containing combination regimen used to treat disseminated …
Effectiveness and pharmacokinetic exposures of first-line drugs used to treat drug-susceptible tuberculosis in children: a systematic review and meta-analysis
Background Optimal doses of first-line drugs for treatment of drug-susceptible tuberculosis in
children and young adolescents remain uncertain. We aimed to determine whether children …
children and young adolescents remain uncertain. We aimed to determine whether children …
The challenges of pharmacokinetic variability of first-line anti-TB drugs
B Devaleenal Daniel, G Ramachandran… - Expert Review of …, 2017 - Taylor & Francis
Introduction: Inter-individual variations in the pharmacokinetics (PK) of anti-TB drugs are
known to occur, which could have important therapeutic implications in patient management …
known to occur, which could have important therapeutic implications in patient management …
Pharmacokinetics of first-line drugs among children with tuberculosis in rural Tanzania
M Justine, A Yeconia, I Nicodemu… - Journal of the …, 2020 - academic.oup.com
Background Dosing recommendations for treating childhood tuberculosis (TB) were revised
by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated …
by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated …